Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

“From 2019 to 2024, the percentage of adult patients with a diagnosis of overweight or obesity increased 50.7 percent, and ...

Aug 14 (Reuters) - More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 ...

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...